Faruqi and Faruqui, LLP Logo
Share this page

Adeptus Health Inc. (ADPT)



Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Adeptus Health Inc. To Contact The Firm Before Lead Plaintiff Deadline

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Adeptus Health Inc. (“Adeptus” or the “Company”) (NYSE: ADPT) of the December 27, 2016 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.

The lawsuit has been filed in the U.S. District Court for the Eastern District of Texas on behalf of all those who purchased Adeptus Class A common shares pursuant to the Company’s secondary public offering (the “SPO”) on or about July 31, 2015, or common shares between April 23, 2015 and November 16, 2015 (the “Class Period”).  The case, Oklahoma Law Enforcement Retirement System v. Adeptus Health Inc. et al, No. 6:16-cv-01243 was filed on October 27, 2016.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by engaging in potential predatory billing practices, particularly with respect to lower acuity level patients.

Specifically, on November 17, 2015, KUSA, an NBC-affiliated television station located in Denver, Colorado, aired a 9WANTS To Know investigative report about the billing practices at Adeptus Health's Colorado First Choice emergency rooms (“ERs”). The report concluded that, after alleged months of investigation, the Company’s ERs routinely treated lower acuity patients at urgent care facilities and excessively billed them for the services rendered.

In response to the airing of the KUSA investigative report, Adeptus’s share price fell from $59.87 per share on November 16, 2015 to a closing price of $46.50 on November 17, 2015—a $13.37 or a 22.3% drop. Furthermore, the stock price has continued to decline since the SPO.

Request more information now by clicking here: www.faruqilaw.com/ADPT. There is no cost or obligation to you.

Take Action

If you invested in Adeptus common stock during the Class Period and would like to discuss your legal rights, visit www.faruqilaw.com/ADPT. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding Adeptus’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class that is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. 

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

685 Third Avenue, 26th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
Telephone: (877) 247-4292 or (212) 983-9330

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    Adeptus Health Inc. (ADPT)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 10/28/2016

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.